18737782. Anti-Trkb Monoclonal Antibodies And Methods Of Use simplified abstract (Regeneron Pharmaceuticals, Inc.)
Anti-Trkb Monoclonal Antibodies And Methods Of Use
Organization Name
Regeneron Pharmaceuticals, Inc.
Inventor(s)
Susan D. Croll of Putnam Valley NY (US)
Anti-Trkb Monoclonal Antibodies And Methods Of Use - A simplified explanation of the abstract
This abstract first appeared for US patent application 18737782 titled 'Anti-Trkb Monoclonal Antibodies And Methods Of Use
The present invention provides antibodies that specifically bind to TrkB and can be used in various methods. These antibodies are neuroprotective and can enhance the survival of retinal ganglion cells in vitro.
- The antibodies are agonist antibodies that can be used to treat diseases or disorders of the eye, such as glaucoma.
- They can also be beneficial in treating other neuronal diseases or disorders characterized by neuronal damage.
- The invention includes antibodies that bind TrkB and mediate cell signaling.
- The antibodies may be fully human and non-naturally occurring.
Potential Applications: - Treatment of eye diseases like glaucoma - Treatment of neuronal diseases or disorders - Cell signaling mediation
Problems Solved: - Lack of effective treatments for neurodegenerative diseases - Need for neuroprotective agents for retinal ganglion cells
Benefits: - Enhanced survival of retinal ganglion cells - Potential for improved treatment outcomes in various diseases - Targeted therapy for specific neuronal disorders
Commercial Applications: Title: Neuroprotective Antibodies for Treating Eye and Neuronal Diseases Description: This technology can be utilized in the pharmaceutical industry for developing novel treatments for eye and neuronal diseases, potentially tapping into a lucrative market segment.
Questions about Neuroprotective Antibodies for Treating Eye and Neuronal Diseases: 1. How do these antibodies specifically target TrkB and mediate cell signaling? 2. What are the potential challenges in developing these antibodies for clinical use?
Original Abstract Submitted
The present invention provides antibodies that bind specifically to TrkB and methods of using the same. According to certain embodiments, the antibodies of the invention are agonist antibodies that are neuroprotective, as shown by their effect on enhancing the survival of retinal ganglion cells in vitro. As such, these agonist antibodies may be used to treat diseases or disorders of the eye, such as, but not limited to glaucoma. In addition, other neuronal diseases or disorders may benefit from treatment with these agonist antibodies, including any disease or disorder characterized in part by neuronal damage. In certain embodiments, the invention includes antibodies that bind TrkB and mediate cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies.